GALT

Galectin Therapeutics Inc.

1.90 USD

Last updated Dec 8, 22:01 UTC

Yesterday HIGH

$1.98

Yesterday LOW

$1.87

52w HIGH

$2.47

52w LOW

$1.02

EPS

-0.24

PE

-7.92

Next Earnings

Mar 28, 2024

Overview News Insider Transactions Government Trades

Galectin Therapeutics Inc. stock is down -9.09% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30.77% of the previous 12 December’s closed higher than November.

Galectin Therapeutics Inc. engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer. Belapectins is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Norcross, United States Of America

Website

galectintherapeutics.com

Benzinga Newsdesk

Fri Mar 3, 2023

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price target.
Happy Mohamed

Thu Mar 2, 2023

Galectin Therapeutics Provides Final Randomization Status Of NAVIGATE, Its Seamless, Adaptive Phase 2b/3 Study of Belapectin In Patients With Liver Cirrhosis Caused By Non-Alcoholic Steatohepatitis

Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, announced that in late December 2022, it ended the enrollment of new patients into NAVIGATE, its
Lisa Levin

Wed Feb 22, 2023

$7M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying

The Dow Jones closed lower by around 700 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga Insights

Tue Feb 7, 2023

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Newsdesk

Tue Jan 24, 2023

Galectin Therapeutics Contribution To Improve Histology Interpretation Of Cirrhotic Liver Biopsies With Machine Learning Published In Prominent Gastroenterology Journal

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the scientific paper, "Machine Learning Liver Histology Scores Correlate
Benzinga Newsdesk

Thu Jan 5, 2023

Galectin Therapeutics Announces The End Of Enrollment Of Navigate, Its Seamless, Adaptive Phase 2B/3 Study Of Belapectin In Patients With Liver Cirrhosis Caused By Non-alcoholic Steatohepatitis
Benzinga Newsdesk

Mon Nov 14, 2022

Galectin Therapeutics Q3 EPS $(0.14), Same YoY

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.14) per share. This is unchanged from the same period last year.
Bill Haddad

Wed Oct 12, 2022

Galectin Therapeutics Receives FDA Approval To Proceed With Combination Immunotherapy Trial In Head And Neck Cancer

-Reuters
Bill Haddad

Thu Oct 6, 2022

Galectin Therapeutics Reports The Outcome Of The Second Data And Safety Monitoring Board Meeting For NAVIGATE Phase 2b/3 Study Of Belapectin; DSMB Concluded That Navigate Can Continue As Designed, Without Modifications
Benzinga Newsdesk

Thu Sep 29, 2022

CORRECTION: Correct Ticker For Galecto Is 'GLTO'

LEWIS JOEL, Director

Thu Nov 30, 2023

GALT Recent Insider Trades and Stock Chart

9,880 shares awarded
LEWIS JOEL, Director

Wed Nov 15, 2023

GALT Recent Insider Trades and Stock Chart

10,303 shares awarded